Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.34 |
| ▸ | CDK2 | P24941 | 11/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.34 |
| ▸ | CDK7 | P50613 | 5/20 | 0.34 |
| ▸ | CCNH | P51946 | 5/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.33 |
| ▸ | CDK9 | P50750 | 7/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.33 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445634 | 0.91 | CDK2 (0.38) | CCNE1CDK2CDK5CDK5R1CDK7 | |
| SCHEMBL3445020 | 0.87 | SYK (0.35) | BCDIN3DCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL3445179 | 0.85 | CCNE1 (0.36) | BCDIN3DCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL3443976 | 0.84 | BCDIN3D (0.35) | BCDIN3DCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL3444829 | 0.84 | BCDIN3D (0.35) | BCDIN3DCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL3444826 | 0.83 | CDK1 (0.42) | CCNE1CDK2CDK5CDK5R1CDK7 | |
| SCHEMBL3445953 | 0.81 | CDK2 (0.49) | CCNE1CDK2CDK5CDK5R1CDK7 | |
| SCHEMBL3444828 | 0.78 | BCDIN3D (0.45) | BCDIN3DCCNE1CDK2CDK5CCNE2 | |
| SCHEMBL3444262 | 0.78 | MAPT (0.36) | BCDIN3DCCNE1CDK2CCNE2CCNA2 | |
| SCHEMBL3445925 | 0.78 | CDK2 (0.48) | CCNE1CDK2CDK5CDK5R1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | claimed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | claimed |
| EP-1539760-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2005-06-15 | — | — | EP | claimed |
| WO-2004018473-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2004-03-04 | — | — | WO | claimed |
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| EP-1539760-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018473-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | BCDIN3D 2919/4885CCNE1 37/4885CDK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.